MedTrace Logo

Effect of Insect-derived Protein Supplements on Protein Synthesis and mTORC1 Activation

NCT05457218 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this study is to determine the ability of insect-derived protein supplements (IPC80 and Whole Buffalo Powder Ynsect®) to activate the mTORC1 pathway and protein synthesis in muscle cells.

To achieve this aim, participants will consume a supplemental dose (0.25 g/kg body weight) of IPC80,Whole Buffalo Powder or whey protein. Blood samples will be drawn before and 15, 30, 60 and 90 minutes after the supplementation.

Protein synthesis will be assessed using stably transfected C2C12 muscle cells with a plasmid (pcDNA3 luciferase) and to determine the ability of a protein source to activate mTORC1, stably transfected C2C12 muscle cells with a plasmid (pcDNA3-TOP luciferase) where the luciferase mRNA contains a 5'TOP. 5'TOP which is specifically regulated by mTORC1 activity will be used.

Conditions

  • Effect of Food Supplement

Interventions

DIETARY_SUPPLEMENT

Whey protein

The participant will consume a supplemental dose of whey protein (0.25 g/kg body weight)

DIETARY_SUPPLEMENT

IPC80

The participant will consume a supplemental dose of IPC80 (0.25 g/kg body weight)

DIETARY_SUPPLEMENT

Whole Buffalo Powder

The participant will consume a supplemental dose of Whole Buffalo Powder (0.25 g/kg body weight)

Sponsors & Collaborators

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Keith Baar, PhD · UC Davis

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2023-06-30
Completion
2024-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05457218 on ClinicalTrials.gov